immunosuppression in bone marrow transplant nwogoh benedict department of haematology/blood...
TRANSCRIPT
![Page 1: Immunosuppression in Bone Marrow Transplant Nwogoh Benedict Department of Haematology/Blood Transfusion, Federal Medical Centre, Owerri BBMT Conference,](https://reader033.vdocuments.site/reader033/viewer/2022051619/56649d9e5503460f94a8926c/html5/thumbnails/1.jpg)
Immunosuppression in Bone Marrow
Transplant
Nwogoh Benedict Department of Haematology/Blood
Transfusion,Federal Medical Centre, Owerri
BBMT Conference, Benin, July 15 - 27, 2013
![Page 2: Immunosuppression in Bone Marrow Transplant Nwogoh Benedict Department of Haematology/Blood Transfusion, Federal Medical Centre, Owerri BBMT Conference,](https://reader033.vdocuments.site/reader033/viewer/2022051619/56649d9e5503460f94a8926c/html5/thumbnails/2.jpg)
Objectives Summarize the principles for use of
immunosuppression in allogeneic stem cell transplant (SCT)
Compare and contrast commonly used medications used for immunosuppression
Describe monitoring parameters and common adverse effects associated with immunosuppression
![Page 3: Immunosuppression in Bone Marrow Transplant Nwogoh Benedict Department of Haematology/Blood Transfusion, Federal Medical Centre, Owerri BBMT Conference,](https://reader033.vdocuments.site/reader033/viewer/2022051619/56649d9e5503460f94a8926c/html5/thumbnails/3.jpg)
Introduction HSCT is a process of reconstituting the
haemopoietic and immunological system of a recipient using previously harvested stem cells from same individual or a donor HSC.
Allogeneic HSCT involves a complex immunological interplay between donor and recipient immune systems with potentials of both beneficial and serious life threatening complications
![Page 4: Immunosuppression in Bone Marrow Transplant Nwogoh Benedict Department of Haematology/Blood Transfusion, Federal Medical Centre, Owerri BBMT Conference,](https://reader033.vdocuments.site/reader033/viewer/2022051619/56649d9e5503460f94a8926c/html5/thumbnails/4.jpg)
Introduction Appropriate manipulation of this
complexity is necessary for a successful transplant.
Immunosuppresion is a important modality of moderating this immunological interaction to ensure a successful HSCT.
![Page 5: Immunosuppression in Bone Marrow Transplant Nwogoh Benedict Department of Haematology/Blood Transfusion, Federal Medical Centre, Owerri BBMT Conference,](https://reader033.vdocuments.site/reader033/viewer/2022051619/56649d9e5503460f94a8926c/html5/thumbnails/5.jpg)
Immune System Innate Immunity
Physical Barriers Secretions with microbiocidal activity Phagocytes
Adaptive/Specific Immunity Humoral Cellular: B, T and Plasma cells
![Page 6: Immunosuppression in Bone Marrow Transplant Nwogoh Benedict Department of Haematology/Blood Transfusion, Federal Medical Centre, Owerri BBMT Conference,](https://reader033.vdocuments.site/reader033/viewer/2022051619/56649d9e5503460f94a8926c/html5/thumbnails/6.jpg)
Cells of the Immune System
![Page 7: Immunosuppression in Bone Marrow Transplant Nwogoh Benedict Department of Haematology/Blood Transfusion, Federal Medical Centre, Owerri BBMT Conference,](https://reader033.vdocuments.site/reader033/viewer/2022051619/56649d9e5503460f94a8926c/html5/thumbnails/7.jpg)
Antigen Major HLA Ags
Class I HLA A, B, C Class II HLA DP, DQ, DR Class III
Minor HLA Ags Non HLA Ags
![Page 8: Immunosuppression in Bone Marrow Transplant Nwogoh Benedict Department of Haematology/Blood Transfusion, Federal Medical Centre, Owerri BBMT Conference,](https://reader033.vdocuments.site/reader033/viewer/2022051619/56649d9e5503460f94a8926c/html5/thumbnails/8.jpg)
http://www.rikenresearch.riken.jp/eng/frontline/5028
![Page 9: Immunosuppression in Bone Marrow Transplant Nwogoh Benedict Department of Haematology/Blood Transfusion, Federal Medical Centre, Owerri BBMT Conference,](https://reader033.vdocuments.site/reader033/viewer/2022051619/56649d9e5503460f94a8926c/html5/thumbnails/9.jpg)
Use of Immunosuppression Immunosuppression is used in allogeneic
stem cell transplant to:
Prevention of rejection
Prophylaxis for graft versus host disease (GVHD)
Treatment of GVHD
![Page 10: Immunosuppression in Bone Marrow Transplant Nwogoh Benedict Department of Haematology/Blood Transfusion, Federal Medical Centre, Owerri BBMT Conference,](https://reader033.vdocuments.site/reader033/viewer/2022051619/56649d9e5503460f94a8926c/html5/thumbnails/10.jpg)
Prevention of rejection Rejection is a consequence of host versus
graft reaction. Immunosuppresants are incuperated into
the conditioning regimen to prevent rejection.
Eradicates host T-cells to allow acceptance of donor cells
Commonly used agents include ATG, Alemtuzimab and Cyclophosphamide.
![Page 11: Immunosuppression in Bone Marrow Transplant Nwogoh Benedict Department of Haematology/Blood Transfusion, Federal Medical Centre, Owerri BBMT Conference,](https://reader033.vdocuments.site/reader033/viewer/2022051619/56649d9e5503460f94a8926c/html5/thumbnails/11.jpg)
Prophylaxis for graft versus host disease (GVHD) Pre- & post-transplant medications Suppresses donor T-cells to minimize
recognition of host cells as foreign Post transplant could be
Ex-vivo manipulation of the graft to deplete it of T cells (TCD)
In-vivo
![Page 12: Immunosuppression in Bone Marrow Transplant Nwogoh Benedict Department of Haematology/Blood Transfusion, Federal Medical Centre, Owerri BBMT Conference,](https://reader033.vdocuments.site/reader033/viewer/2022051619/56649d9e5503460f94a8926c/html5/thumbnails/12.jpg)
Treatment of GVHD The first line agent is usually steroids
(methylprednisolone 1-2mg/kg) A calcineurine inhibitor (Cyclosporine) may be
used in combination. Second line agent may be indicated when first
line fails. First line agent is adjudged to have failed
when : Features are progressive after 3 days of steroid
therapy Failure to respond after 14 days of therapy
![Page 13: Immunosuppression in Bone Marrow Transplant Nwogoh Benedict Department of Haematology/Blood Transfusion, Federal Medical Centre, Owerri BBMT Conference,](https://reader033.vdocuments.site/reader033/viewer/2022051619/56649d9e5503460f94a8926c/html5/thumbnails/13.jpg)
Pathophysiology of GVHD
Ferrara, et al. Lancet 2009;373:1550-61.
![Page 14: Immunosuppression in Bone Marrow Transplant Nwogoh Benedict Department of Haematology/Blood Transfusion, Federal Medical Centre, Owerri BBMT Conference,](https://reader033.vdocuments.site/reader033/viewer/2022051619/56649d9e5503460f94a8926c/html5/thumbnails/14.jpg)
Medications used for immunosuppressionClass Drug
Immune globulin Antithymocyte globulin (ATG) - Equine ATG: Atgam
- Rabbit ATG: Thymoglobulin
Monoclonal antibody Alemtuzumab - Campath
Calcineurin Inhibitors Tacrolimus - Prograf
Cyclosporine - Non-modified: SandIMMUNE
- Modified: Gengraf or Neoral
Antifolate antimetabolite Methotrexate
Immunosuppressant Mycophenolate mofetil - CellCept
Corticosteroids MethylprednisolonePrednisone
mTOR inhibitor Sirolimus - Rapamune
![Page 15: Immunosuppression in Bone Marrow Transplant Nwogoh Benedict Department of Haematology/Blood Transfusion, Federal Medical Centre, Owerri BBMT Conference,](https://reader033.vdocuments.site/reader033/viewer/2022051619/56649d9e5503460f94a8926c/html5/thumbnails/15.jpg)
Alemtuzumab Anti CD52
monoclonal antibody CD52 expressed on:
B and T lymphocytes Monocytes Macrophages NK cells Dendritic cells
www.nature.com/reviews/drugdisc
![Page 16: Immunosuppression in Bone Marrow Transplant Nwogoh Benedict Department of Haematology/Blood Transfusion, Federal Medical Centre, Owerri BBMT Conference,](https://reader033.vdocuments.site/reader033/viewer/2022051619/56649d9e5503460f94a8926c/html5/thumbnails/16.jpg)
Alemtuzumab Adverse Effects Infusion related reactions
Chills, dyspnea, fevers, hypotension, rigors May be fatal
Premedicate with acetaminophen, diphenhydramine, ± corticosteroid
Hypersensitivity reactions Cytokine release syndrome Opportunistic infections
Requires anti-infective prophylaxis
![Page 17: Immunosuppression in Bone Marrow Transplant Nwogoh Benedict Department of Haematology/Blood Transfusion, Federal Medical Centre, Owerri BBMT Conference,](https://reader033.vdocuments.site/reader033/viewer/2022051619/56649d9e5503460f94a8926c/html5/thumbnails/17.jpg)
Antithymocyte Globulin (ATG)
Mohty. Leukemia.2007, 21:1387-94.
![Page 18: Immunosuppression in Bone Marrow Transplant Nwogoh Benedict Department of Haematology/Blood Transfusion, Federal Medical Centre, Owerri BBMT Conference,](https://reader033.vdocuments.site/reader033/viewer/2022051619/56649d9e5503460f94a8926c/html5/thumbnails/18.jpg)
Antithymocyte Globulin Polyclonal antibodies active against T cells Administration
Infuse over at least 6 hours Premedicate with acetaminophen,
corticosteroids, and an antihistamine Rabbit ATG (Thymoglobulin®) and equine ATG
(Atgam ®) are NOT interchangeable
![Page 19: Immunosuppression in Bone Marrow Transplant Nwogoh Benedict Department of Haematology/Blood Transfusion, Federal Medical Centre, Owerri BBMT Conference,](https://reader033.vdocuments.site/reader033/viewer/2022051619/56649d9e5503460f94a8926c/html5/thumbnails/19.jpg)
Antithymocyte Globulin Adverse effects
Infusion-related reactions Fever, chills, headache
Hypersensitivity reactions Cytokine release syndrome Increased risk of infections Serum sickness
![Page 20: Immunosuppression in Bone Marrow Transplant Nwogoh Benedict Department of Haematology/Blood Transfusion, Federal Medical Centre, Owerri BBMT Conference,](https://reader033.vdocuments.site/reader033/viewer/2022051619/56649d9e5503460f94a8926c/html5/thumbnails/20.jpg)
Calcineurin inhibitors
http://www.nature.com/nrneph/journal/v2/n12/fig_tab/ncpneph0343_F2.html
![Page 21: Immunosuppression in Bone Marrow Transplant Nwogoh Benedict Department of Haematology/Blood Transfusion, Federal Medical Centre, Owerri BBMT Conference,](https://reader033.vdocuments.site/reader033/viewer/2022051619/56649d9e5503460f94a8926c/html5/thumbnails/21.jpg)
Calcineurin Inhibitors Inhibit T cell activation by suppressing
production of IL-2 IV Administration
Non-PVC tubing Continuous infusion over 24 hours
IV:PO conversion = ~1:3 Therapeutic Drug Monitoring (TDM)
PO: trough levels (30 min prior to dose)
![Page 22: Immunosuppression in Bone Marrow Transplant Nwogoh Benedict Department of Haematology/Blood Transfusion, Federal Medical Centre, Owerri BBMT Conference,](https://reader033.vdocuments.site/reader033/viewer/2022051619/56649d9e5503460f94a8926c/html5/thumbnails/22.jpg)
Calcineurin Inhibitors: Adverse Effects Nephrotoxicity Hypertension Hyperglycemia Hypercholesterolemia Hypomagnesemia Hyperkalemia HUS/TTP CNS toxicity
Tremor Posterior reversible encephalopathy syndrome
(PRES)
![Page 23: Immunosuppression in Bone Marrow Transplant Nwogoh Benedict Department of Haematology/Blood Transfusion, Federal Medical Centre, Owerri BBMT Conference,](https://reader033.vdocuments.site/reader033/viewer/2022051619/56649d9e5503460f94a8926c/html5/thumbnails/23.jpg)
Calcineurin Inhibitors: Drug Interactions
Many others CYP3A4 inducers and inhibitors
Anti-fungals
Antibiotics GI Agents Anti-convulsants
Others
Fluconazole Metronidazole Metoclopramide Phenytoin Protease inhibitors
Voriconazole Erythromycin Cimetidine Phenobarbital Sirolimus
Posaconazole Clarithromycin Lansoprazole Carbamazepine St. John’s wort
Ketoconazole Rifampin Grapefruit juice
![Page 24: Immunosuppression in Bone Marrow Transplant Nwogoh Benedict Department of Haematology/Blood Transfusion, Federal Medical Centre, Owerri BBMT Conference,](https://reader033.vdocuments.site/reader033/viewer/2022051619/56649d9e5503460f94a8926c/html5/thumbnails/24.jpg)
Calcineurin Inhibitors: Cyclosporine Dosing
3 mg/kg CIVI over 24 hours (initial) 5-6 mg/kg PO every 12 hours (initial) Modified ≠ non-modified May mix oral solution with
orange juice TDM
150-350 ng/ml Adverse effects
Hirsutism/hypertrichosis Gingival hyperplasia
![Page 25: Immunosuppression in Bone Marrow Transplant Nwogoh Benedict Department of Haematology/Blood Transfusion, Federal Medical Centre, Owerri BBMT Conference,](https://reader033.vdocuments.site/reader033/viewer/2022051619/56649d9e5503460f94a8926c/html5/thumbnails/25.jpg)
Methotrexate Mechanism of action
Induces apoptosis of activated lymphocytes Blocks dihydrofolate reductase to inhibit purine
synthesis Dosing
5-15 mg/m2 IVP on D+1, 3, 6, 11 +/- leucovorin rescue
Adverse effects Mucositis Myelosuppression Hepatotoxicity
![Page 26: Immunosuppression in Bone Marrow Transplant Nwogoh Benedict Department of Haematology/Blood Transfusion, Federal Medical Centre, Owerri BBMT Conference,](https://reader033.vdocuments.site/reader033/viewer/2022051619/56649d9e5503460f94a8926c/html5/thumbnails/26.jpg)
![Page 27: Immunosuppression in Bone Marrow Transplant Nwogoh Benedict Department of Haematology/Blood Transfusion, Federal Medical Centre, Owerri BBMT Conference,](https://reader033.vdocuments.site/reader033/viewer/2022051619/56649d9e5503460f94a8926c/html5/thumbnails/27.jpg)
Mycophenolate mofetil Mechanism of action
Inhibits lymphocyte proliferationby blocking purine synthesis
Dosing 1000 mg PO/IV every 12 hours
Drug interactions Calcium & magnesium
Adverse effects Nausea, vomiting, diarrhea Myelosuppression
![Page 28: Immunosuppression in Bone Marrow Transplant Nwogoh Benedict Department of Haematology/Blood Transfusion, Federal Medical Centre, Owerri BBMT Conference,](https://reader033.vdocuments.site/reader033/viewer/2022051619/56649d9e5503460f94a8926c/html5/thumbnails/28.jpg)
![Page 29: Immunosuppression in Bone Marrow Transplant Nwogoh Benedict Department of Haematology/Blood Transfusion, Federal Medical Centre, Owerri BBMT Conference,](https://reader033.vdocuments.site/reader033/viewer/2022051619/56649d9e5503460f94a8926c/html5/thumbnails/29.jpg)
Corticosteroids Mechanism of action
Affect number & function of B-cells & T-cells Dosing
Systemic Methylprednisolone or prednisone 0.5-2 mg/kg IV/PO
daily Taper when applicable
Topical Budesonide-SR 3 mg PO every 8-12 hours (gut GVHD) Triamcinolone cream 0.1% to body +/-
hydrocortisone 1% to face (skin GVHD)
![Page 30: Immunosuppression in Bone Marrow Transplant Nwogoh Benedict Department of Haematology/Blood Transfusion, Federal Medical Centre, Owerri BBMT Conference,](https://reader033.vdocuments.site/reader033/viewer/2022051619/56649d9e5503460f94a8926c/html5/thumbnails/30.jpg)
Corticosteroid Adverse Effects Short term
Hyperglycemia Mood disturbance,
psychosis Insomnia Hypertension Fluid retention Skin atrophy Gastric ulcers
Long term Adrenal suppression Moon facies Weight gain Osteoporosis Buffalo hump Cataracts Myopathy Infections
![Page 31: Immunosuppression in Bone Marrow Transplant Nwogoh Benedict Department of Haematology/Blood Transfusion, Federal Medical Centre, Owerri BBMT Conference,](https://reader033.vdocuments.site/reader033/viewer/2022051619/56649d9e5503460f94a8926c/html5/thumbnails/31.jpg)
Sirolimus Mechanism of action
Inhibits proliferation of lymphocytes by blocking m-TOR
Dosing 12 mg PO x 1 then 4 mg PO once daily
Therapeutic Drug Monitoring (TDM) 3-12 ng/ml Trough levels (30 min prior to dose)
![Page 32: Immunosuppression in Bone Marrow Transplant Nwogoh Benedict Department of Haematology/Blood Transfusion, Federal Medical Centre, Owerri BBMT Conference,](https://reader033.vdocuments.site/reader033/viewer/2022051619/56649d9e5503460f94a8926c/html5/thumbnails/32.jpg)
http://www.nature.com/nrneph/journal/v2/n12/fig_tab/ncpneph0343_F2.html
![Page 33: Immunosuppression in Bone Marrow Transplant Nwogoh Benedict Department of Haematology/Blood Transfusion, Federal Medical Centre, Owerri BBMT Conference,](https://reader033.vdocuments.site/reader033/viewer/2022051619/56649d9e5503460f94a8926c/html5/thumbnails/33.jpg)
Sirolimus Drug interactions
Similar to calcineurin inhibitors(CYP 3A4)
Adverse effects Hyperlipidemia Myelosuppression Pneumonitis Thrombotic microangiopathy
![Page 34: Immunosuppression in Bone Marrow Transplant Nwogoh Benedict Department of Haematology/Blood Transfusion, Federal Medical Centre, Owerri BBMT Conference,](https://reader033.vdocuments.site/reader033/viewer/2022051619/56649d9e5503460f94a8926c/html5/thumbnails/34.jpg)
Additional Immunosuppressants: Treatment for GVHD TNFα blockers
Etanercept, infliximab Pentostatin Alefacept
Many drugs under investigation for treatment of acute and chronic GVHD
![Page 35: Immunosuppression in Bone Marrow Transplant Nwogoh Benedict Department of Haematology/Blood Transfusion, Federal Medical Centre, Owerri BBMT Conference,](https://reader033.vdocuments.site/reader033/viewer/2022051619/56649d9e5503460f94a8926c/html5/thumbnails/35.jpg)
Infection Prevention
Use appropriate anti-infective prophylaxis throughout immunosuppressive therapy Pneumocystis carinii pneumonia Fungal infections Viral infections
![Page 36: Immunosuppression in Bone Marrow Transplant Nwogoh Benedict Department of Haematology/Blood Transfusion, Federal Medical Centre, Owerri BBMT Conference,](https://reader033.vdocuments.site/reader033/viewer/2022051619/56649d9e5503460f94a8926c/html5/thumbnails/36.jpg)
Summary Immunosuppression is utilized in
allogeneic SCT to prevent rejection and GVHD, and for the treatment of GVHD
Infectious complications are common, making appropriate anti-infective prophylaxis important
![Page 37: Immunosuppression in Bone Marrow Transplant Nwogoh Benedict Department of Haematology/Blood Transfusion, Federal Medical Centre, Owerri BBMT Conference,](https://reader033.vdocuments.site/reader033/viewer/2022051619/56649d9e5503460f94a8926c/html5/thumbnails/37.jpg)
Stem Cell Unit, Dept of Haematology, Blood Transfusion and Stem Cell Transplantation . Physician:Bazuaye G. N 05.07.2013Patient: Matthew Ebenezer, DOB: 23.11.1997Diagnosis: Sickle Cell Anaemia Donor: Matthew Naomi (MSD), Genotype: AAConditioning: Flu 180 mg/m2, Bu 16mg/kg, ATG (ATGAM) 1500mg total dose over 3days, CSA 5mg/kg/day. (analog EBMT 2005 Sykora und Sauer et al.) Weight. 48 kg, Height 175 cm, BSA 1.53 m2
PROTOCOL
![Page 38: Immunosuppression in Bone Marrow Transplant Nwogoh Benedict Department of Haematology/Blood Transfusion, Federal Medical Centre, Owerri BBMT Conference,](https://reader033.vdocuments.site/reader033/viewer/2022051619/56649d9e5503460f94a8926c/html5/thumbnails/38.jpg)
References Ashley Newland. Notes on Immunosuppression in
Bone Marrow Transplant. Eliane Gluckman. Choice of the donor according
toHLA typing and stem cell source. In EBMT HSCT handbook 6th Edition
Jane Appley. Graft versus host disease. In EBMT HSCT handbook 6th Edition
![Page 39: Immunosuppression in Bone Marrow Transplant Nwogoh Benedict Department of Haematology/Blood Transfusion, Federal Medical Centre, Owerri BBMT Conference,](https://reader033.vdocuments.site/reader033/viewer/2022051619/56649d9e5503460f94a8926c/html5/thumbnails/39.jpg)
Thank You!